Suppr超能文献

含有传染性支气管炎病毒刺突蛋白和H3N2流感病毒血凝素的重组融合蛋白在鸡体内的免疫原性和保护效果

Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens.

作者信息

Yin Lijuan, Zeng Yuyao, Wang Wei, Wei Ying, Xue Chunyi, Cao Yongchang

机构信息

State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China.

Linyi Institute for Food and Drug Control, Linyi, Shandong Province, PR China.

出版信息

Virus Res. 2016 Sep 2;223:206-12. doi: 10.1016/j.virusres.2016.07.010. Epub 2016 Aug 3.

Abstract

Infectious bronchitis (IB) is an acute and highly contagious viral respiratory disease of chickens and vaccination is the main method for disease control. The S1 protein, which contains several virus neutralization epitopes, is considered to be a target site of vaccine development. However, although protective immune responses could be induced by recombinant S1 protein, the protection rate in chickens was still low (<50%). Here, we generated fused S1 proteins with HA2 protein (rS1-HA2) or transmembrane domain and cytoplasmic tail (rS1-H3(TM)) from hemagglutinin of H3N2 influenza virus. After immunization, animals vaccinated with fusion proteins rS1-HA2 and rS1-H3(TM) demonstrated stronger robust humoral and cellular immune responses than that of rS1 and inactivated M41 vaccine. The protection rates of groups immunized with rS1-HA2 (87%) were significantly higher than the groups inoculated with rS1 (47%) and inactivated M41 vaccine (53%). And chickens injected with rS1-H3(TM) had similar level of protection (73%) comparing to chickens vaccinated with rS1 (47%) (P=0.07). Our data suggest that S1 protein fused to the HA2 or TM proteins from hemagglutinin of H3N2 influenza virus may provide a new strategy for high efficacy recombinant vaccine development against IBV.

摘要

传染性支气管炎(IB)是鸡的一种急性且高度传染性的病毒性呼吸道疾病,疫苗接种是疾病控制的主要方法。包含多个病毒中和表位的S1蛋白被认为是疫苗开发的靶点。然而,尽管重组S1蛋白可诱导保护性免疫反应,但鸡的保护率仍然较低(<50%)。在此,我们构建了与H3N2流感病毒血凝素的HA2蛋白(rS1-HA2)或跨膜结构域及胞质尾(rS1-H3(TM))融合的S1蛋白。免疫后,接种融合蛋白rS1-HA2和rS1-H3(TM)的动物表现出比rS1和灭活M41疫苗更强的体液免疫和细胞免疫反应。接种rS1-HA2的组(87%)的保护率显著高于接种rS1的组(47%)和灭活M41疫苗的组(53%)。与接种rS1的鸡(47%)相比,注射rS1-H3(TM)的鸡具有相似的保护水平(73%)(P=0.07)。我们的数据表明,与H3N2流感病毒血凝素的HA2或TM蛋白融合的S1蛋白可能为开发针对传染性支气管炎病毒的高效重组疫苗提供一种新策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验